RT Journal Article
SR Electronic
T1 Fast spread of COVID-19 in Europe and the US suggests the necessity of early, strong and comprehensive interventions
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.04.04.20050427
DO 10.1101/2020.04.04.20050427
A1 Ke, Ruian
A1 Sanche, Steven
A1 Romero-Severson, Ethan
A1 Hengartner, Nick
YR 2020
UL http://medrxiv.org/content/early/2020/04/15/2020.04.04.20050427.abstract
AB The COVID-19 pandemic caused more than 800,000 infections and 40,000 deaths by the end of March 2020. However, some of the basic epidemiological parameters, such as the exponential epidemic growth rate and R0 are debated. We developed an inference approach to control for confounding factors in data collection, such as underreporting and changes in surveillance intensities, and fitted a mathematical model to infection and death count data collected from eight European countries and the US. In all countries, the early epidemic grew exponentially at rates between 0.19-0.29/day (epidemic doubling times between 2.4-3.7 days). This suggests a highly infectious virus with an R0 likely between 4.0 and 7.1. We show that similar levels of intervention efforts are needed, no matter the goal is mitigation or containment. Early, strong and comprehensive intervention efforts to achieve greater than 74-86% reduction in transmission are necessary.One-sentence Summary We estimated that COVID-19 spreads rapidly in 8 European countries and the US, suggesting that early, strong and comprehensive interventions are necessary.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe work is partially funded by the Laboratory Directed Research and Development (LDRD) Rapid Response Program through the Center for Nonlinear Studies at Los Alamos National Laboratory. RK and SS would like to acknowledge funding from DARPA (HR0011938513), the Center for Nonlinear Studies. ERS was funded though NIH grant (R01AI135946).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is available in the main text or the supplementary materials.